Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan and Paratek reports positive findings from acne drug trial

Allergan and Paratek reports positive findings from acne drug trial

28th March 2017

Allergan and Paratek Pharmaceuticals have reported new clinical trial data showing the effectiveness of their new treatment for acne.

Results have been reported from two phase III trials evaluating sarecycline for the treatment of moderate to severe acne, showing that both studies met their 12-week primary efficacy endpoints.

The once-daily oral antibiotic was shown to deliver significant benefits in addressing inflammatory acne lesions when compared to placebo, highlighting the drug's strong potential as a new option for physicians treating acne.

Based on these positive findings, Allergan will file for US regulatory approval of sarecycline in this indication during the second half of the year.

David Nicholson, chief global research and development officer at Allergan, said: "The positive efficacy results observed in the pivotal phase III clinical trials indicate that sarecycline can be an effective treatment option for patients with moderate to severe acne."

Sarecycline has been specifically designed for inflammatory acne and rosacea, and holds the potential to be a best-in-class therapeutic solution.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801834018-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.